These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32242306)

  • 1. Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma.
    Ishigaki K; Hamada T; Nakai Y; Ishigaki Y; Oyama H; Kanai S; Suzuki T; Nakamura T; Sato T; Hakuta R; Saito K; Saito T; Takahara N; Mizuno S; Kogure H; Tateishi R; Tada M; Koike K
    Clin J Gastroenterol; 2020 Aug; 13(4):568-571. PubMed ID: 32242306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma.
    Suoh M; Fujii H; Nagata Y; Kotani K; Hagihara A; Enomoto M; Tamori A; Inaba M; Kawada N
    Clin J Gastroenterol; 2020 Oct; 13(5):860-866. PubMed ID: 32128670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
    Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
    Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
    Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
    Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
    Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
    Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
    Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
    Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
    Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
    Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
    Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
    Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.
    Gomez-Abuin G; Karam AA; Mezzadri NA; Bas CA
    Clin Genitourin Cancer; 2009 Jan; 7(1):62-3. PubMed ID: 19213671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
    Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
    Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute acalculous cholecystitis with eosinophilic infiltration.
    Muta Y; Odaka A; Inoue S; Komagome M; Beck Y; Tamura M; Arai E
    Pediatr Int; 2015 Aug; 57(4):788-91. PubMed ID: 26315204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
    Watanabe T; Koyama N
    Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma.
    Suoh M; Hagihara A; Yamamura M; Maruyama H; Taira K; Enomoto M; Tamori A; Fujiwara Y; Kawada N
    Intern Med; 2021 Feb; 60(4):545-552. PubMed ID: 33028766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of chronic acalculous cholecystitis diagnosed by delayed contrast emptying in gallbladder].
    Kim CW; Lee JM; Coh J; Jung IS; Kang KM; Jung SH; Lee GS; Kim A; Kwak SS; Lee MS
    Korean J Gastroenterol; 2004 May; 43(5):320-3. PubMed ID: 15156120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma].
    Choi SW; Lee JM; Kim DG; Noh MH
    Korean J Gastroenterol; 2020 Feb; 75(2):103-107. PubMed ID: 32098465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.
    Sato A; Imai Y; Uchiya H; Uchida Y; Nakazawa M; Sugawara K; Nakayama N; Mochida S
    Intern Med; 2022 Aug; 61(15):2301-2305. PubMed ID: 35283380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
    Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
    Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
    Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
    Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute ischemic cholecystitis after transarterial chemoembolization of hepatocellular carcinoma: incidence and clinical outcome.
    Wagnetz U; Jaskolka J; Yang P; Jhaveri KS
    J Comput Assist Tomogr; 2010; 34(3):348-53. PubMed ID: 20498534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.